Their Curo46 engine's unique algorithms identify complex relationships and meaningful patterns, based on millions of variables, and based upon current models is designed to determine risks of specific illnesses.
General Genomics leverages multiple sources of data, including health history, test results, and other relevant information with its proprietary artificial intelligence expertise to understand an individuals' risk for disease, illness, and the probability of treatment success, efficacy, and side effects. Whereas, these patients respond to anti-infectives, anti-inflammatory and immune modulatory treatments, but the next advancement would be if we could predict which treatments would be most effective prior to use."
"We have learned through research and clinical testing, that if a patient's neurologic or psychiatric symptoms are a result of an underlying autoimmune dysfunction, traditional psychotropic drugs are often ineffective, and sometimes can contribute to worsening symptoms. "The brain is the last frontier of medicine," says Craig Shimasaki, PhD, MBA, Co-Founder and CEO of Moleculera Labs. The sudden onset of these symptoms has been associated with common infections that result in cross-reactive autoantibodies directed against portions of the brain, in particular the basal ganglia. Patients may be characterized by obsessive compulsive disorders, anxiety, food restriction, phobia, depression, and a host of other symptoms. The company has tested over 13,000 patients suffering from Autoimmune Encephalopathy and Basal Ganglia Encephalitis (AE/BGE) such as PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococci) and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome), portions of autism spectrum disorders (ASD), ADD/ADHD, chronic depression, and anxiety disorders. is a precision medicine company focused on identifying the underlying root of neurologic, psychiatric, and behavioral disorders. Moleculera Labs and General Genomics Form Strategic Alliance to Utilize Proprietary AI to Provide Personalized Medicine for Autoimmune Neuropsychiatric Disorders
0 kommentar(er)
